SN

Savvas Neophytou

Chief Investment Officer. Deepbridge Capital LLP

Birkenhead, England

Invests in

Locations:

  • Min Investment:

    $1,000,000.00
  • Max Investment:

    $10,000,000.00
  • Target Investment:

    $5,000,000.00

Education

Work Experience

  • Chief Investment Officer

    2016

    Deepbridge Capital is a Technology Venture Business with a clear focus upon the commercialisation of emerging technologies with global reach. Our areas of focus include Life Science, Eco-Innovation and Digital Technologies. Within Life Sciences, we believe passionately in the country’s innovation capability and take an engaged hands-on approach with our portfolio companies to help them grow. We recognise that small companies may not always have all the necessary skills in-house and thus we provide support where it’s needed until the businesses mature enough to have all the necessary tools to scale up.

  • Co-founder, Director

    2016 - 2018

  • Founder

    2016 - 2016

    Torafugu Tech helps health and life insurers increase product personalisation and improve the health & wellbeing of their members. Using data from wearables, sensors and cell phones our digital health platform utilises state of the art AI analytics, combined with the provision of expert knowledge and behaviour nudges to help members live a healthier, happier and more productive life.

2015 - 2015

  • Group CEO

    2015 - 2015

    Telehealth organisation offering video consultations with doctors via mobile telephones as well as procuring the delivery of prescriptions and medicines to patients.

2007 - 2015

  • Executive Director

    2007 - 2015

    Pharmaceuticals, Healthcare & Biotechnology ECM

  • Research analyst

    2006 - 2007

    Pharmaceuticals & biotechnology analyst

2004 - 2006

  • Associate director

    2004 - 2006

    Head of Life Sciences, split time between corporate finance when advising life sciences companies and research as the day job

2001 - 2004

  • Research Analyst

    2001 - 2004

    Coverage pan-European mid-cap Pharma, Novartis, Roche, GSK, AZN

2000 - 2001

  • Corporate Finance

    2000 - 2001

    Generalist M&A